Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cox Survey Finds Federal Regulations Are Lowest Barrier To Becoming A ‘Smart Hospital’

Executive Summary

Medtech Insight spoke to Cox Communications VP George Valentine about the main obstacles facing hospitals trying to become “smart hospitals.”

You may also be interested in...



Digital Health Roundup: HIMSS, Cardio Conversations, ChatGPT And New FDA Guidances

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb discusses how two medtech CEOs are and aren’t using ChatGPT in their businesses while Reed Miller talks about his “Cardio Conversations” podcast interviews with Quentin Blackford, CEO of iRhythm, and Rob Krummen, CEO of Vektor Medical. Washington, DC-based reporter Hannah Daniel reviews highlights from the HIMSS conference and the latest updates on FDA guidances.

How Two Medtech CEOs Are (And Aren’t) Using ChatGPT In Their Businesses

Two medtech executives talked to Medtech Insight about how they started integrating ChatGPT into their start-ups to help with writing marketing copy, develop websites and presentations, identify KOLs and conferences, and other content.

Q&A: IMDRF Releases Final Legacy Device Cybersecurity Guidance

The International Medical Device Regulation Forum published its final guidance on principles and practices for legacy medical devices, and the document seems to be less about legacy devices and more about the total lifecycle of a device, compliance expert Eric Henry told Medtech insight.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel